Stryker (SYK) investor relations material

Strategic direction and resilience

• Continues to prioritize innovation, M&A, and specialized business growth, with no major strategic shifts expected despite leadership changes.

• Emphasizes strong operational resilience and customer focus, especially following a significant cyber incident that temporarily disrupted manufacturing.

• Maintains confidence in full-year guidance, expecting recovery from the cyber event to phase across Q2–Q4, with accelerated growth in the second half due to new product launches.

• No changes to sales incentives post-cyber event, reflecting confidence in workforce motivation and demand.

• Capital backlog remains strong, with order growth outpacing shipments and additional production capacity being added.

Financial outlook and recovery

• Revenue impact from the cyber incident is expected to be recovered throughout the year, with some back-end loading due to production ramp-up and hospital scheduling constraints.

• Margin expansion target of 150 basis points over three years is supported by operational excellence and OpEx leverage.

• Tariff reductions and potential refunds are offsetting some cyber-related cost pressures, with timing of refunds expected over the year.

• Inflation and supply chain exposures are being closely monitored, but current impacts are immaterial; proactive cost controls were implemented early.

• Pricing strategy remains stable, with modest improvements expected, especially in MedSurg, and the ability to pass on costs through contracts.

Innovation, portfolio, and M&A

• Robust innovation pipeline highlighted by new products in neurosurgery, orthopedics, and MedSurg, as well as successful M&A activity.

• Mako robotic platform continues to see record demand, with new product introductions like Mako RPS expanding market reach.

• Ortho Tech business combines robotics and power tools for strategic differentiation and customer alignment.

• M&A remains the top capital allocation priority, with a focus on adjacencies in cardiovascular, neuromodulation, and healthcare IT.

• Soft tissue robotics is monitored as a potential opportunity but not considered essential; valuation shifts in the market may create new M&A prospects.